Healthcare Costs Associated with Osteoarthritis in US Patients

摘要: Background:  Osteoarthritis is a chronic debilitating condition affecting many adults in the United States. This study was to compare pharmacologic treatments and costs for newly diagnosed existing osteoarthritis patients assess unmet medication treatment needs economic burden. Methods:  retrospective analysis of de-identified medical pharmacy insurance claims from MarketScan® databases identified adult with an claim 2007. The date first 2007 served as index. Patients were stratified into cohorts, based on presence claim(s) over 12-month pre-index period. Utilization pain-related medications healthcare assessed postindex Multivariate conducted adjust controlling cross-cohort differences. Results:  Newly (n = 134,584) younger (66.0 vs. 68.0, P < 0.001), had higher proportion men (37.4% 33.9%, P < 0.001) but lower rates comorbidities than (n = 123,653). Significantly proportions inpatient admission outpatient office visit. Higher utilized majority classes examined. Total adjusted osteoarthritis-related $6,811 annually (95% confidence interval [CI] $6,743 $6,887), compared $6,407 CI $6,327 $6,477) patients. Costs prescription drugs associated $965 $955 $975) among new patients, less $1,117 $1,107 $1,129) patients. Conclusion:  incurred annual costs, drug year following diagnosis osteoarthritis.